Sedana Medical (SEDANA.ST) Stock Analysis & AI Equity Report
Sedana Medical (SEDANA.ST) overview
Sedana Medical (SEDANA.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Sedana Medical reported revenue of SEK 200m and operating profit of SEK -32.2m; the year-end share price was 10.28 SEK and market capitalisation was SEK 1,021m. Sedana Medical is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Sedana Medical's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Sedana Medical
Sedana Medical is a medtech and pharmaceutical company focused on inhaled sedation for mechanically ventilated patients in intensive care. Its portfolio includes the Sedaconda ACD medical device and Sedaconda (isoflurane), which are used together to deliver sedation. The company sells directly in several European markets and uses distributors in other regions, while also preparing for a future US launch.
Generate the Sedana Medical report
Sedana Medical is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Sedana Medical and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.